The World Carcinoembryonic Antigen Market is Projected to Reach at a CAGR of 6.7% by 2023

November 2418:192017

Carcinoembryonic Antigen Market

Market Research Future publishes a half cooked research report on the Global Carcinoembryogenic Antigen Market, Which is Projected to Reach at a CAGR of 6.7% by 2023

Carcinoembryogenic antigen (CEA) is a group of glycoproteins which are produced during the fetal developmental stages by gastrointestinal tissues. CEA is responsible for cell adhesion. Healthy adults do not have CEA concentrations. However, smoking and certain medical conditions such as colorectal cancer, breast cancer etc. can mark the presence of CEA in the body. Thus, CEA based diagnostic assays are used for the detection of such cancers and to check the treatment efficiency during the therapeutic period by a physician.

In 2017, studies of the NCBI suggested that the global burden of colorectal cancer will increase by 60%, leading to 2.2 million new cancer cases and 1.1 million deaths by 2030. This will increase the colorectal cancer diagnostic demands, thereby propelling the market growth.

Increasing prevalence of cancer, rising healthcare expenditures, and developing diagnostic technologies will boost the global market during the forecast period. However, risk of infection and hematoma, lack of awareness and medical services in the developing countries will restrain the market growth during the assessment period.

The Americas account for the largest share in the carcinoembryogenic antigen market. The Americas mainly include countries like the U.S. and Canada. Increasing prevalence of cancer and high healthcare expenditures within the region will boost the market growth over the assessment period.

Europe is the second highest revenue generating region in the global carcinoembryogenic antigen market. Increasing prevalence of cancer, fast adoption of new technologies and presence of developed countries like Germany and U.K within the region will boost the market growth during the forecasted period.

On account of the developing medical infrastructure, rising healthcare expenditure, and increasing government initiatives, Asia Pacific region is expected to grow the fastest.

The Middle East & Africa is expected to grow slower than the global average. The Middle Eastern countries, for instance, UAE and Saudi Arabia dominates the market due to high income and the government support to improve public health.

The global carcinoembryonic antigen market has been segmented on the basis of application, sampling, and end user.

Based on application, the market has been segmented into colorectal, pancreatic, breast, lung cancer, and others.

Based on sampling, the market has been segmented into antecubital, peritoneal, pleural, serebrospinal, and others.

Based on the end users, the market has been segmented into hospitals, diagnostic centers, research centers, and others.

The report Global Carcinoembryogenic Antigen Marketby Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.